Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi-Aventis To File For Menactra Use In Infants

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm sees pharmacoeconomic advantage for two-dose regimen at nine and 12 months.

You may also be interested in...

Sanofi Pasteur Nets Flu Vaccine Via Acambis Purchase

Early C. difficile program comes along with $550 million deal.

Sanofi Pasteur’s Five-In-One Vaccine Approved

Next step for Pentacel is the June 25 ACIP Vaccines for Children vote.

Novartis Meningitis Blockbuster Strategy Key To Firm’s Vaccine Growth

Novartis plans to submit ACWY meningitis BLA in the second half, putting Menveo on track for approval in 2009.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts